EDGAR Filing Documents for 0001193125-18-127305

Form 8-K - Current report:

SEC Accession No. 0001193125-18-127305

Filing Date

2018-04-24

Accepted

2018-04-23 21:27:33

Documents

Period of Report

2018-04-19

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	d574637d8k.htm	8-K	32194
2	EX-2.1	d574637dex21.htm	EX-2.1	318979
3	EX-10.1	d574637dex101.htm	EX-10.1	173551
4	EX-99.1	d574637dex991.htm	EX-99.1	39992
5	EX-99.2	d574637dex992.htm	EX-99.2	30798
6	GRAPHIC	g574637dsp01.jpg	GRAPHIC	3927
	Complete submission text file	0001193125-18-127305.txt		602408

Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037

Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600

Orexigen Therapeutics, Inc. (Filer) CIK: 0001382911 (see all company filings)